Cho Esther 4/A

What happened Esther Cho, Chief Legal Officer of Keros Therapeutics (KROS), was granted 80,000 derivative shares (an option/award) on February 24, 2026. The award is reported at $0.00 (no cash paid at grant) and is recorded as a derivative acquisition. This is a compensation grant rather than an open‑market purchase or sale.

Key details

• Transaction date and price: 2026-02-24; 80,000 derivative shares granted at $0.00.
• Vesting: One-quarter (25%) vests on Feb 24, 2027; the remaining 75% vests in 12 substantially equal quarterly installments thereafter (i.e., roughly quarterly over the next 3 years).
• Shares owned after transaction: Not reported in the amended Form 4.
• Filing status: This is an amended Form 4 filed Mar 27, 2026 to correct an earlier Form 4 (filed Feb 26, 2026) that misstated an earliest transaction date; the amendment corrects reporting data and is not indicated as late.

Context This filing documents a standard equity compensation grant (derivative/option) to a company executive. Such grants do not involve an immediate open‑market purchase and reflect expected future compensation that vests over time. The award will only translate into exercisable or owned shares as vesting and any exercise or tax withholding actions occur.